Objective. Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last 2 decades, and direct medical costs may differ by types of treatments. There has not been a systematic literature review since the introduction of new RA treatments, including biologic disease-modifying antirheumatic drugs (bDMARDs). Methods. We conducted a systematic literature review with meta-analysis of direct medical costs associated with RA patients cared for in the US since the marketing of the first bDMARD. Standard search strategies and sources were used, and data were extracted independently by 2 reviewers. The methods and quality of included studies were assessed. Total direct medical costs as well as RA-specific costs were calculated using random-effects meta-analysis. Subgroups of interest included Medicare patients and those using bDMARDs. Results. We found 541 potentially relevant studies, and 12 articles met the selection criteria. The quality of studies varied: one-third were poor, one-third were fair, and one-third were good. Total direct medical costs were estimated at $12,509 (95% confidence interval [95% CI] 7,451-21,001) for all RA patients using any treatment regimen and $36,053 (95% CI 32,138-40,445) for bDMARD users. RA-specific costs were $3,723 (95% CI 2,408-5,762) for all RA patients using any treatment regimen and $20,262 (95% CI 17,480-23,487) for bDMARD users. Conclusion. The total and disease-specific direct medical costs for patients with RA is substantial. Among bDMARD users, the cost of RA care is more than half of all direct medical costs.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune systemic disease affecting approximately 0.7% of the population (1) . Treatment for RA was transformed in the late 1990s with the advent of biologic disease-modifying antirheumatic drugs (bDMARDs) targeting specific immunologic pathways. As a disease with early adoption of bDMARDs, RA serves as a model for the use of biologic drugs, where the treatment costs vary substantially based on therapeutic strategy. Biologic DMARDs offer alternatives for patients unresponsive to traditional synthetic DMARDs, but the drugs carry an increased financial burden, with annual costs between $25,000 and $40,000. Thus, a detailed understanding of the cost of care for patients with RA since the advent of bDMARDs will be of importance to policy-makers, administrators, and physicians. The high cost of RA treatments impacts the use of limited medical resources.
There is a body of primary literature examining the cost of RA since the introduction of bDMARDs, but a current critical review of these studies is lacking. The most recent reviews on cost-of-care research for RA in the US were published before the advent of biologics (2) (3) (4) . Several more recent reviews have been published looking at costs outside of the US (5, 6) , but these studies have limited relevance to the US, given the difficulties of comparing costs across health care systems with different payment structures and social priorities.
The question of direct medical costs for patients with RA is further complicated by the complexities and lack of standardization in the methodology of cost-of-care analyses. When conducting a cost-of-care analysis, researchers must make decisions about the best source of data, the case definition for RA, the financial measure, referred to as "costs," the elements of medical costs to be included, and the assignment of costs to RA versus other concurrent morbid diseases. Given the need for better understanding of cost of care for RA in the US and the need for standardization in cost-of-care analysis, we undertook a systematic literature review and meta-analysis with the following PICOS assignments: P (patients) = RA patients in the US since 1999; I (interventions) = any treatment regimen for RA; C (comparator) = no comparison group was included; O (outcomes) = direct medical costs; and S (study design) = all study types were included. We also examined the methodology used in relevant studies.
MATERIALS AND METHODS
Study selection. Studies were identified through a search of Medline using the following medical subject heading search terms: cost of illness; health care costs; expenditures; expenditures, direct; expenditures, health; expenditures, indirect; rheumatoid arthritis; and arthritis, rheumatoid (full search strategy available in Supplementary Appendix A, available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10. 1002/acr.23512/abstract). Because this analysis was meant to consider only studies assessing costs after the introduction of bDMARDs in 1999, the search was limited to studies published in or after 2000. The last search we performed was on June 16, 2016.
Citations were screened by 1 reviewer (AH) for eligibility criteria to select articles for full-text review. Criteria for inclusion were English language, focus on a US population, analysis of post-1999 data, and consideration of total direct costs of treatment for RA from a provider, insurer, or societal perspective. Studies were excluded if they were nonEnglish language, focused on musculoskeletal or rheumatic disorders other than RA, did not analyze cost as an outcome, were review articles or conference abstracts, focused on a population outside the US, focused on indirect costs, failed to analyze key elements of total direct cost, studied a nongeneralizable population (e.g., only patients with a specific comorbidity), were economic evaluations of specific drugs or therapies, relied on pre-1999 data, or provided an insufficient description of their cost-analysis methodology. Reference lists of studies deemed potentially relevant were examined for articles not identified by the Medline search. Full-text review of potentially relevant studies was performed independently by 2 reviewers (AH and DHS) to confirm eligibility.
Data abstraction and quality rating. Two independent reviewers abstracted data from included studies using a standardized form (see Supplementary Appendix B, available on the Arthritis Care & Research web site at http:// onlinelibrary.wiley.com/doi/10.1002/acr.23512/abstract). Information abstracted from each study included the characteristics of study participants, such as age, sex, comorbidities, and health insurance coverage, the study's inclusion and exclusion criteria, cost analysis methodology, and cost-ofcare findings. Specific aspects of the cost analysis examined were the definition of RA, methods for comparisons with costs of non-RA patients, the overall costing methodology, and adjustment for inflation. Regarding costing methodology, some articles used the frequency of utilization of specific services and multiplied this frequency by a predefined dollar amount; we defined this practice as the utilization 9 standardized cost. All abstracted costs were converted to 2015 dollars using the consumer price index medical care component.
Additionally, we developed a quality rating form based on the Newcastle-Ottawa Quality Assessment Form for Cohort Studies (7), modified to facilitate assessment of RA cost-of-illness analyses (see Supplementary Appendix C, available on the Arthritis Care & Research web site at http:// onlinelibrary.wiley.com/doi/10.1002/acr.23512/abstract). The quality rating included assessment of the representativeness of the studied cohort to assess for risk of selection bias. The same 2 reviewers who abstracted data also independently rated the quality of included studies. Disagreements regarding data abstraction or quality ratings were resolved by discussion between the 2 reviewing authors.
Meta-analysis. The description of the meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist (see Supplementary  Table 1 , available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23512/ abstract). The analysis of costs used a pooled estimate from random-effects models. The variance of the pooled estimates was stabilized by the double arcsine transformation. This method was found to produce less bias and mean squared error than the traditional log transformation (8).
We assessed heterogeneity among studies using Cochran's Q statistic and quantified inconsistencies across studies and their impact on the analysis by using the I 2 statistic (9). All analyses were done using MetaXL software, version 1.4 (http://www.epigear.com).
RESULTS
Study selection. The Medline search yielded 541 citations, and all abstracts were reviewed. Of these, 523
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• We conducted a systematic literature review with meta-analysis of direct medical costs associated with rheumatoid arthritis (RA) patients cared for in the US since the marketing of the first biologic disease-modifying antirheumatic drugs (bDMARDs).
• The 12 articles that met the selection criteria demonstrated that total direct medical costs were $12,509 (95% confidence interval [95% CI] 7,451-21,001) for all RA patients using any treatment regimen and $36,053 (95% CI 32,138-40,445) for bDMARD users.
• RA-specific costs were $3,723 (95% CI 2,408-5,762) for all RA patients using any treatment regimen and $20,262 (95% CI 17,480-23,487) for bDMARD users.
• Among bDMARD users, the cost of RA care is more than half of all direct medical costs.
were discarded because they did not meet inclusion criteria ( Figure 1 ). Of those citations excluded based on abstracts, 364 were excluded because they were not cost-ofillness analyses, 68 because they examined non-US data, 62 because they focused on indirect costs or only a subset of total costs, 18 because they used data from years prior to 1999, and 11 because they focused on a population that could not be generalized to a national sample, such as only patients with a specific comorbidity or using a specific drug. After full-text review of the remaining 18 articles, 6 did not meet the inclusion criteria (2 were excluded because they did not describe their costing methodology sufficiently for comparison to other included articles, 2 because their populations could not be generalized, and 2 because on further inspection their sample included data from years prior to 1999). A total of 12 studies were identified for inclusion in the review.
Data sources, populations, and quality assessment. Table 1 shows the data sources and patient characteristics of the 12 studies included in final analyses. The included studies used a total of 16 different sources of patient data for their cost analyses. Only 1 database, the Medical Expenditure Panel Survey, was used in more than 1 of the included studies. The included studies analyzed costs within a number of different medical insurance settings; 6 studies reported costs for privately insured patients (10-15), 3 studies reported costs for patients enrolled in Medicaid programs (12, 16, 17) , and 1 study reported costs for patients enrolled in Medicare (18) . Additionally, 3 studies used patient data from large, national databases and used weighting to generalize their findings to be representative of the entire US population (19) (20) (21) . One article (12) incorporated costs from multiple insurance settings in the same set of analyses.
Identification of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes in the 714.xx series in medical claims was the most common method for identifying RA patients in claims databases; only 1 study (19) did not rely on ICD-9-CM codes in some capacity for patient identification. However, there was considerable variability in which codes were used and the number of instances of an RA code required for inclusion. Of the 11 studies using ICD-9-CM codes, 4 identified a narrow subset of codes to define RA (10, (15) (16) (17) , while the rest accepted any code within the 714.xx series (11) (12) (13) (14) 18, 20, 21) . Eight studies (73%) required only 1 instance of an RA code for inclusion; the remaining 3 (27%) required >1 instance of an RA code, or a combination of 1 RA code with either a claim for at least 1 DMARD or self-reported RA diagnosis.
Most studies included all patients with RA in their chosen database; however, 4 studies limited their population to only those patients using bDMARDs. All studies, by design, analyzed costs incurred after 1999, but none analyzed the costs incurred after 2010. There was an even distribution in the quality of included studies according to our established quality assessment framework: 4 studies were judged to be of poor quality, 4 were fair quality, and 4 were good quality. However, in all studies the observed cohort was deemed to be adequately representative of a national sample, indicating little risk of selection bias.
Cost-of-illness analysis methods. Details on the cost analysis methodologies used in the included studies are shown in Table 2 . The vast majority of studies based their cost analysis on actual reimbursements paid by an insurer for medical services or drugs as reported in a claims database. Michaud et al (19) and Weycker et al (10) instead employed a utilization-based method in which they applied a consistent standardized dollar amount to each instance of utilization of a given medical service or drug as reported in a claims database. For a second database, Weycker et al based their cost analysis on charges billed by a health care institution for medical services and drugs, as opposed to the actual reimbursed amount. The findings of Weycker et al yielded the highest cost estimates in our data set.
Of the 12 included studies, 10 reported at least 1 element of cost, such as costs of hospitalizations, ambulatory care, or prescription drugs, specific to care for RA as opposed to other comorbid diagnoses. Of those, 8 reported RA-specific costs across 3 cost domains and were included in the metaanalysis of total RA costs.
Cost-of-care findings. Among the 8 studies including all RA patients (not only those using a biologic DMARD) in their analyses (12, 14, (16) (17) (18) (19) (20) (21) , findings for annual total cost of care across all conditions ranged from $3,266 to $25,260, with the lowest estimate being in a population of Medicaid enrollees and the highest in a Medicare population ( Table 3) . Notably, the low estimate of $3,266 (17) is much lower than any other finding, being only 28% of the nextlowest estimate. Meta-analysis of studies including all RA patients found annual total cost of care to be $12,509 (95% confidence interval [95% CI] 7,451-21,001) (Figure 2A ). Removing the low estimate did not substantially change the total cost of care ($12,458 [95% CI 7,381-21,025]). Among studies restricted to RA patients using bDMARDs, annual total cost of care ranged from $26,469 to $52,837, with the lower estimate representing privately insured working-age adults and the higher estimate privately insured adults ages <65 years. Meta-analysis found annual total cost of care among patients using biologics to be $36,053 (95% CI 32,138-40,445) ( Figure 2B ). Estimates for annual cost for RA-specific care ranged considerably. Estimates in studies including patients using any treatment regimen (i.e., not limited to bDMARD users only) ranged from $2,437 to $7,849 (Table 3) , with the lower estimate representing a population modeling the general US population and the higher representing Medicaid enrollees. Meta-analysis determined annual cost for RA-specific care to be $3,723 (95% CI 2,408-5,762) when accounting for patients using any treatment regimen ( Figure 2C ), representing 30% of total costs for all care. Estimates of RA-specific costs in studies limiting their population to patients using bDMARDs ranged from $16,716 to $22,445, with both estimates being based on different claims databases comprising privately insured working-age adults. Meta-analysis found annual RA-specific cost within this population to be $20,262 (95% CI 17,480-23,487) ( Figure 2D ), representing 56% of total costs for all care.
DISCUSSION
RA is a morbid, mortal, and costly illness. The cost of treating RA has increased over the last 2 decades with the advent of bDMARDs, but this increase has not been well studied. We conducted a systematic literature review and analyzed prior cost-of-care studies for RA; the cost of direct medical care for a patient with RA was $12,509 and the costs attributable to RA were $3,725, or 30% of the total costs. Among patients receiving bDMARDs, total direct medical costs were $36,053, and costs attributable to RA were $20,262, or 56% of the total.
These findings suggest that costs associated with RA are in line with those for other prominent chronic diseases. Recent studies have reported the annual total direct cost of care for diabetes mellitus patients as $14,732 (22) , multiple sclerosis patients as $23,195 (23) , ulcerative colitis patients between $4,032 and $13,722 (24) , and patients with chronic obstructive pulmonary disease between $1,681 and $10,812 (25), using 2015 dollars. Our findings also suggest that the burden of RA patients on the US health care system may become outsized compared to the disease's relatively small prevalence and compared to patients with these other chronic conditions as more patients use bDMARDs in the future.
The observed costs show that patients who use bDMARDs had increased costs compared with typical RA patients. Additionally, bDMARD use had a larger incremental effect on RA-specific costs (444% increase) than on total direct medical costs (188% increase). However, in both cases the increment was below the total cost of bDMARDs themselves. This gap suggests that either the use of bDMARDs may be associated with lower total nondrug direct medical costs or that the patients who receive bDMARDs have fewer comorbid conditions. Research comparing the characteristics of bDMARD users versus regular DMARD users has shown differences in the demographic and clinical characteristics of bDMARD users compared to regular DMARD users (26, 27) , and this topic is worthy of further examination.
While the cost of RA is extremely important to the health care system, the methodologies observed and used across the included prior studies varied substantially. The definition of RA differed, what were considered costs and their calculation were not standardized, and the attempt to partition RA costs from non-RA costs differed by study. Two predominant methods were used to identify RA-specific costs: de-identification of claims with an RA-related ICD-9-CM diagnosis code, and determination of the incremental costs between a population of RA patients versus a population of controls. Both methods have their limitations. Identification of claims with RA-related codes fails to address the possibility that claims may be misclassified as being RA-related or not, based on a coding error. Likewise, assessment of incremental cost is subject to error in the nuance of defining a non-RA control population, especially in the consideration of which comorbidities may or may not be related to the pathophysiology of RA. In addition, the quality of reporting in the included studies was inconsistent.
The methods for studying direct medical costs need further standardization. Standardized methods would facilitate comparison across studies with less concern for heterogeneity and would also allow for better temporal trend analyses, ensuring "apples-to-apples" comparisons. Ideal methods would account for all inpatient, outpatient, prescription medication, and post-acute care costs, rely on actual reimbursement amounts reported in claims as the basis of analysis, define RA patients by requiring multiple instances of an RA-related diagnosis code in claims, assess both total cost for all medical care and RA-specific care, and compare costs between RA patients and similar patients without RA from the same database.
The current meta-analysis is limited by the literature we included. As noted, the methods across studies were not consistent, and this limitation increases the uncertainty of our summarized results. Since we did not have individual patient-level data, we could not examine the associations between individual patient characteristics and cost. As well, the methods for partitioning RA costs were inconsistent, making the RA-specific cost analyses more difficult to interpret. Finally, we did not include studies of indirect costs of RA, such as work lost and caregiver costs. While indirect costs are substantial (9, 28, 29) , the methodologic variability is also significant; thus, we worried about introducing even more heterogeneity in this meta-analysis.
In light of these limitations, we conclude that the direct medical costs for patients with RA are significant. Clearly, medication costs comprise a substantial portion of these costs, especially for patients using bDMARDs. Without considering the health effects, benefits, and risks, the current analysis cannot comment on whether specific treatments are of value. Cost-effectiveness analyses comparing different treatment strategies for RA are ongoing and will provide useful information. The studies included in this metaanalysis do not include assessments of RA outcomes, but our findings may be a valuable resource for future costeffectiveness analyses that will further understanding of the relative benefits of treatment options available to RA patients. As standards of care evolve in RA, the standards for studying the cost of care in RA must also mature and become codified. This codification will facilitate better comparisons across treatments and across time.
